ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
다발성 골수종 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.0%로 성장할 전망이며, 381억 6,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 의료 기술의 통합, 원격의료 서비스 채용, 개인화 백신요법, 환자교육을 위한 디지털 헬스 플랫폼 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향은 표적 요법의 진보, 신약 개발, 면역 요법의 진보, 신규 바이오마커 개발, 인공지능 통합 등이 있습니다.
향후 5년간의 성장률 8.0%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세 장벽은 스위스나 독일에서 공급되는 CAR-T 세포 요법 및 프로테아좀 억제제의 비용을 상승시키고, 구명 치료를 지연시키며, 암 의료비를 상승시킴으로써 미국에 지장을 초래할 것으로 예측됩니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.
다발성 골수종 시장의 성장이 기대되는 것은 이러한 암의 유병률 증가 때문입니다. 플라즈마 세포에서 발생하는 다발성 골수종은 연령, 유전, 비만, 방사선 노출 등의 요인에 영향을 받습니다. 미국 암학회가 보고하고 있듯이, 증례 수 증가는 분명하며, 신규 증례 수는 2022년의 34,470례에서 2023년에는 35,730례로 증가했습니다. 이러한 유병률 증가는 다발성 골수종 치료에서 진보의 필요성을 강조하고 시장 성장에 기여합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 다발성 골수종 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 다발성 골수종 시장 : 성장률 분석
세계의 다발성 골수종 시장 실적 : 규모 및 성장(2019-2024년)
세계의 다발성 골수종 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 다발성 골수종 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 다발성 골수종 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
의약품
방사선 치료
줄기세포 이식
기타 치료법
세계의 다발성 골수종 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
혈액 검사
골수 생검
소변 검사
화상 검사
세계의 다발성 골수종 시장 : 질환 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
활성 다발성 골수종
흔들리는 다발성 골수종
세계의 다발성 골수종 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
기타 채널
세계의 다발성 골수종 시장 : 의약품 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역조절제(IMiDs)
프로테아좀 억제제
단일클론항체
코르티코스테로이드
화학 요법제
세계의 다발성 골수종 시장 : 방사선 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
외부 방사선 치료(EBRT)
방사성동위원소 요법
세계의 다발성 골수종 시장 : 줄기세포 이식 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
자가 줄기세포 이식(ASCT)
동종 줄기세포 이식
세계의 다발성 골수종 시장 : 기타 치료법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
지지요법
임상시험 및 실험적 치료
제7장 지역별 및 국가별 분석
세계의 다발성 골수종 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 다발성 골수종 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
다발성 골수종 시장 : 경쟁 구도
다발성 골수종 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Private Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bayer AG
Novartis AG
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca plc
Abbott Laboratories
GlaxoSmithKline PLC
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Boehringer Ingelheim International GmbH
Amgen Inc.
Janssen Global Services LLC
Celgene Corporation
Mylan NV
Biogen Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
다발성 골수종 시장(2029년) : 새로운 기회를 제공하는 국가
다발성 골수종 시장(2029년) : 새로운 기회를 제공하는 부문
다발성 골수종 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Multiple myeloma is a form of cancer originating in a type of white blood cell known as a plasma cell. In this condition, cancerous plasma cells accumulate in the bone marrow, displacing healthy blood cells. The cancer cells produce abnormal proteins that can lead to complications rather than contributing to the production of beneficial antibodies.
The primary treatments for multiple myeloma encompass various approaches such as medications, radiation therapy, stem cell transplant, and others. Medications, in this context, refer to dosage forms containing both potentially inert substances and one or more active chemicals aimed at managing the disease. To diagnose active multiple myeloma and smoldering multiple myeloma, healthcare professionals employ blood tests, bone marrow biopsy, urine tests, and imaging tests. Treatment modalities can be administered through different channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The multiple myeloma research report is one of a series of new reports from The Business Research Company that provides multiple myeloma market statistics, including the multiple myeloma industry's global market size, regional shares, competitors with multiple myeloma market share, detailed multiple myeloma market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma industry. This multiple myeloma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The multiple myeloma market size has grown strongly in recent years. It will grow from $26.07 billion in 2024 to $28.05 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to diagnostic improvements, the introduction of stem cell transplantation, access to high-quality medical care, precision medicine approaches, and patient-centric care models.
The multiple myeloma market size is expected to see strong growth in the next few years. It will grow to $38.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to health technology integration, adoption of telemedicine services, personalized vaccine therapies, and digital health platforms for patient education. Major trends in the forecast period include advancements in targeted therapies, novel drug development, immunotherapy advancements, novel biomarker development, and integration of artificial intelligence.
The forecast of 8.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of CAR-T cell therapies and proteasome inhibitors sourced from Switzerland and Germany, thereby delaying life-saving treatments and elevating oncology care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth in the multiple myeloma market is expected to be driven by the increasing prevalence of this form of cancer. Multiple myeloma, which originates in plasma cells, is influenced by factors such as age, genetics, obesity, and radiation exposure. The rise in the number of cases is evident, as reported by the American Cancer Society, with new cases increasing from 34,470 in 2022 to 35,730 in 2023. This escalation in prevalence underscores the imperative for advancements in multiple myeloma treatments, thereby contributing to the growth of the market.
The growth in healthcare expenditures is poised to propel the multiple myeloma market forward. Healthcare expenditures, representing the total monetary outlay on healthcare goods and services within a defined period, play a significant role in the treatment and management of multiple myeloma. These expenditures cover various aspects, including therapies, medications, hospitalization, and supportive care. As indicated by the Canadian Institute for Health Information (CIHI) in November 2022, the forecasted rise in total health spending in Canada from $328 billion in 2021 to $331 billion in 2022 reflects the increasing financial commitment to healthcare. This upward trend in healthcare expenditures is expected to drive advancements in multiple myeloma treatment options and contribute to the overall growth of the market.
Product innovation stands out as a prominent trend in the multiple myeloma market, with major companies actively engaged in developing innovative therapies to maintain their competitive positions. In October 2022, Janssen Pharmaceutical Companies of Johnson & Johnson achieved FDA approval for TECVAYLI (teclistamab-cqyv), the first bispecific T-cell engager antibody. This drug is intended for the treatment of adult patients with multiple myeloma who have undergone at least four prior lines of therapy, including various drugs. TECVAYLI targets the B-cell maturation antigen (BCMA) expressed on certain B-lineage cells, as well as the CD3 receptor found on T-cells and multiple myeloma cells.
Major players in the multiple myeloma market are also focusing on the development of novel therapies such as CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) to gain a competitive advantage. In December 2023, Bristol Myers Squibb received approval for Abecma, the first CAR T-cell therapy for earlier use in patients with relapsed or refractory multiple myeloma who have undergone at least two prior therapies. Abecma, a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy, demonstrated significant improvements in median progression-free survival (mPFS) and overall response rate (ORR) based on the interim analysis of the KarMMa-3 Phase 3 study.
In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition highlights AstraZeneca's strategic effort to bolster its presence in immuno-oncology and cellular therapies by leveraging Gracell's cutting-edge platform and expertise. Gracell Biotechnologies Inc., a China-based company, specializes in the clinical development of FasTCAR-T GC012F for the treatment of multiple myeloma.
Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.
North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the multiple myeloma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The multiple myeloma market consists of revenues earned by entities by providing services such as treatment planning, supportive care, and diagnostic testing such as computerized tomography (CT scans), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma market also includes sales of thalidomide, bortezomib, and daratumumab which are used in providing multiple myeloma services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Multiple Myeloma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on multiple myeloma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for multiple myeloma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The multiple myeloma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Medications; Radiation Therapy; Stem Cell Transplant; Other Treatments
2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Urine Tests; Imaging Tests
3) By Disease Type: Active Multiple Myeloma; Smoldering Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Channels
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Multiple Myeloma Market Characteristics
3. Multiple Myeloma Market Trends And Strategies
4. Multiple Myeloma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Multiple Myeloma Growth Analysis And Strategic Analysis Framework
5.1. Global Multiple Myeloma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Multiple Myeloma Market Growth Rate Analysis
5.4. Global Multiple Myeloma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Multiple Myeloma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Multiple Myeloma Total Addressable Market (TAM)
6. Multiple Myeloma Market Segmentation
6.1. Global Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Radiation Therapy
Stem Cell Transplant
Other Treatments
6.2. Global Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Bone Marrow Biopsy
Urine Tests
Imaging Tests
6.3. Global Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Active Multiple Myeloma
Smoldering Multiple Myeloma
6.4. Global Multiple Myeloma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Channels
6.5. Global Multiple Myeloma Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunomodulatory Drugs (IMiDs)
Proteasome Inhibitors
Monoclonal Antibodies
Corticosteroids
Chemotherapy Agents
6.6. Global Multiple Myeloma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy (EBRT)
Radioisotope Therapy
6.7. Global Multiple Myeloma Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autologous Stem Cell Transplant (ASCT)
Allogeneic Stem Cell Transplant
6.8. Global Multiple Myeloma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Supportive Care
Clinical Trials And Experimental Therapies
7. Multiple Myeloma Market Regional And Country Analysis
7.1. Global Multiple Myeloma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Multiple Myeloma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
